近30年老兵回归强生中国，跨国药企为何在华密集换帅

澎湃新闻07-15

继礼来、葛兰素史克（GSK）、诺华、飞利浦等跨国医药企业后，强生中国正式官宣医疗科技业务新负责人。7月15日，强生中国对外宣布，周敏涛将于7月25日起担任旗下医疗科技中国区总裁，向强生医疗科技亚太区主席Vishnu Karla汇报，并成为强生医疗科技亚太区领导团队成员之一。今年4月，时任强生中国区主席、强生医疗科技中国区总裁宋为群提出辞呈，寻求外部发展机会。根据当时的消息，宋为群将在今年9月底前...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2451643645?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-15 18:53","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2451643645","market":"us","top_or_hot":-1,"title":"近30年老兵回归强生中国，跨国药企为何在华密集换帅","media":"澎湃新闻","content":"<div>\n<p>继礼来、葛兰素史克（GSK）、诺华、飞利浦等跨国医药企业后，强生中国正式官宣医疗科技业务新负责人。7月15日，强生中国对外宣布，周敏涛将于7月25日起担任旗下医疗科技中国区总裁，向强生医疗科技亚太区主席Vishnu Karla汇报，并成为强生医疗科技亚太区领导团队成员之一。今年4月，时任强生中国区主席、强生医疗科技中国区总裁宋为群提出辞呈，寻求外部发展机会。根据当时的消息，宋为群将在今年9月底前...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151853429f4e7968&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>近30年老兵回归强生中国，跨国药企为何在华密集换帅</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n近30年老兵回归强生中国，跨国药企为何在华密集换帅\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-15 18:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151853429f4e7968&s=b><strong>澎湃新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>继礼来、葛兰素史克（GSK）、诺华、飞利浦等跨国医药企业后，强生中国正式官宣医疗科技业务新负责人。7月15日，强生中国对外宣布，周敏涛将于7月25日起担任旗下医疗科技中国区总裁，向强生医疗科技亚太区主席Vishnu Karla汇报，并成为强生医疗科技亚太区领导团队成员之一。今年4月，时任强生中国区主席、强生医疗科技中国区总裁宋为群提出辞呈，寻求外部发展机会。根据当时的消息，宋为群将在今年9月底前...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151853429f4e7968&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1221951046.USD","symbol_name":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151853429f4e7968&s=b","article_id":"2451643645","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407151853429f4e7968&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2451643645","pubTimestamp":1721040780,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"今年4月，时任强生中国区主席、强生医疗科技中国区总裁宋为群提出辞呈，寻求外部发展机会。1985年，强生进入中国，目前在华设有10余家法律实体，5大供应链基地。今年1月，礼来中国宣布迎来新任总裁兼总经理Huzur Devletsah，这是礼来中国首位女性掌门人。2022年财报显示，礼来中国区收入14.53亿美元，同比下降13%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","BK4559":"巴菲特持仓","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK4581":"高盛持仓","BK4504":"桥水持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","JNJ":"强生","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4592":"伊斯兰概念","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC"},"translate_title":"Veterans have returned to Johnson & Johnson China in the past 30 years. Why are multinational pharmaceutical companies changing coaches intensively in China?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"继礼来、葛兰素史克（GSK）、诺华、飞利浦等跨国医药企业后，强生中国正式官宣医疗科技业务新负责人。7月15日，强生中国对外宣布，周敏涛将于7月25日起担任旗下医疗科技中国区总裁，向强生医疗科技亚太区主席Vishnu Karla汇报，并成为强生医疗科技亚太区领导团队成员之一。今年4月，时任强生中国区主席、强生医疗科技中国区总裁宋为群提出辞呈，寻求外部发展机会。根据当时的消息，宋为群将在今年9月底前继续担任中国区主席及强生医疗科技中国区总裁职务，全面负责公司的经营业务和日常管理，确保平稳过渡和交接。宋为群自2003年起就进入强生工作，是强生公司130多年历史上首位本土成长起来的中国区主席，其离任让业内颇为惊讶，其继任者会是谁也受到行业关注。此次周敏涛履职的消息是自宋为群宣布辞任后的首次官方任命。值得注意的是，根据官方发布的消息，周敏涛的职位是医疗科技中国区总裁，并不包括宋为群此前的中国区主席一职。强生成立于1886年，总部在美国，2023年分拆消费者健康业务后，主要覆盖医疗科技和创新制药两大板块。1985年，强生进入中国，目前在华设有10余家法律实体，5大供应链基地。旗下的医疗科技业务于1994年进入中国市场，专注于外科、骨科和心血管及专业解决方案等领域。即将履新强生医疗科技的周敏涛此前是丹纳赫旗下生物科技公司思拓凡大中华区总裁，但回看其职业生涯，他是在强生公司拥有近三十年工作经验的老兵。周敏涛1992年加入强生消费品业务担任销售代表，曾先后在强生消费品业务以及强生医疗科技旗下的爱惜康事业部工作。2021年底，周敏涛离开强生，入职丹纳赫，此次是时隔两年多的回归。在跨国医药企业全球业务架构调整的大背景下，今年以来，已经有多家跨国医疗健康公司官宣在华掌门人的变化，但具体原因各异。今年1月，礼来中国宣布迎来新任总裁兼总经理Huzur Devletsah，这是礼来中国首位女性掌门人。这一岗位此前的负责人是贝栎铭，他在礼来中国履职一年多后离任。有业内观点认为，这次礼来高管变动与中国区业绩承压有一定关系。2022年财报显示，礼来中国区收入14.53亿美元，同比下降13%。2023年半年报显示，礼来中国区收入7.72亿美元，同比下降3%。GSK和诺华在中国区换帅发生在今年5月，原因都是前负责人升职。具体来看，齐欣升任为GSK大中华和洲际区域副总裁兼疫苗业务负责人，原GSK副总裁兼中国台湾地区总经理余慧明接任成为GSK副总裁兼中国总经理；诺华原中国区掌门人张颖升任诺华国际业务部首席商务官，诺华日本总裁Leo Lee被任命为中国区总裁。在医疗器械领域，7月3日，飞利浦宣布，何国伟决定退休，刘令即日起出任飞利浦大中华区总裁，并成为飞利浦全球执行委员会委员，向飞利浦全球首席执行官贾博瑞汇报。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451643645"}